Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : XNW27011
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Astellas Licenses XNW27011 from Evopoint Targeting CLDN18.2 in Cancer Therapy
Details : The agreement grants Astellas a worldwide exclusive license to develop and commercialize XNW27011, a novel investigational ADC targeting CLDN18.2 for solid tumors.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : $130.0 million
May 28, 2025
Lead Product(s) : XNW27011
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $1,540.0 million
Deal Type : Licensing Agreement
Lead Product(s) : XNW29016
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
PARG Inhibitor XNW29016 in Advanced Solid Tumors After Standard Treatment
Details : XNW29016 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2025
Lead Product(s) : XNW29016
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XNW28012
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
Details : XNW28012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : XNW28012
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XNW27011
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Details : XNW27011 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 24, 2025
Lead Product(s) : XNW27011
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XNW5004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 15, 2025
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Details : XNW5004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : XNW5004
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XNW5004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : XNW5004
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XNW5004
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XNW5004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : XNW5004
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XNW5004
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XNW5004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : XNW5004
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XNW5004,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Evopoint will sponsor the Phase Ib/II trial and MSD will supply KEYTRUDA®. Evopoint maintains the global rights to XNW5004. XNW5004 is a rationally designed, highly selective and potent small molecule inhibitor of EZH2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 06, 2023
Lead Product(s) : XNW5004,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration